Skip to main content
Premium Trial:

Request an Annual Quote

Arrayit Pursuing PMA from FDA for OvaDx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Microarray firm Arrayit today said that it will be seeking pre-market approval by the US Food and Drug Administration for its OvaDx ovarian cancer test.

In a statement, the Sunnyvale, Calif., firm said that though the PMA process is more stringent than the 510(k) route, it believes it can receive Class III PMA approval for the test.

"We have carefully considered the technical and regulatory issues with respect to OvaDx and have decided that a PMA submission, though more demanding that a 510(k0K, is the most appropriate pathway to market for our ovarian cancer screening test," said Arrayit CEO and Chairman Rene Schena in a statement.

The FDA regulates in vitro diagnostic devices under three classes. Class I devices are considered the least risky and subjected to pre-market 510(k) notification, while Class II devices are considered to be riskier than Class I products and are subject to pre-market 510(k) approval. Class III devices are considered the riskiest and subject to PMA.

The OvaDx test is based on Arrayits proprietary microarray platform to identify about 100 protein biomarkers in serum and detect ovarian cancer as early as five years in advance of any symptoms, the company said.

Arrayit did not say when it would be filing its application with the FDA.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.